| 2024-04-02 |
复牌提示：
2024-04-02 11:28:36 停牌，复牌日期 2024-04-02 11:38:36
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-203.57美元,归母净利润-2.53亿美元,同比去年增长-283.6%
|
| 2024-04-01 |
财报披露：
美东时间 2024-04-01 盘后发布财报
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-28.25美元,归母净利润-3509.3万美元,同比去年增长58.74%
|
| 2023-08-09 |
详情>>
股本变动：
变动后总股本124.21万股
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-21.1美元,归母净利润-2620.5万美元,同比去年增长63.20%
|
| 2023-06-05 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.69美元,归母净利润-1682.4万美元,同比去年增长31.39%
|
| 2023-04-27 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.To elect two directors as Class III directors, to serve on the board of directors, each for a three-year term expiring on the date of our 2026 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.An advisory vote to approve the compensation of our Named Executive Officers.
4.An advisory vote on the frequency of holding future executive compensation advisory votes every one year, two years, or three years.
5.To consider such other business as may properly come before the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”).
|
| 2023-03-16 |
详情>>
内部人交易：
COHEN RON共交易2笔
|
| 2023-03-15 |
详情>>
业绩披露：
2022年年报每股收益-3.34美元,归母净利润-6591.6万美元,同比去年增长36.59%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-4.69美元,归母净利润-8505.8万美元,同比去年增长-2%
|
| 2022-09-22 |
股东大会：
将于2022-11-04召开股东大会
会议内容 ▼▲
- 1.Approval of an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 61,666,666 to 100,000,000 in order to provide a sufficient number of authorized shares for possible future corporate finance, business development, equity compensation and other general corporate purposes.
2.Authorizing our Board of Directors to approve an amendment and restatement of our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number in the range of 1-for-2 to 1-for-20 within one year following the Special Meeting. If implemented, this amendment also would result in a proportionate reduction in the number of shares of our common stock that are outstanding and that are authorized for issuance, after taking into account the increase in the number of authorized shares if stockholders approve the prior proposal.
3.Approval of one or more adjournments of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the preceding proposals at the time of the Special Meeting, or in the absence of a quorum. This would authorize the Board to adjourn the Special Meeting to solicit votes on the approval of either or both of the above proposals.
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-4.74美元,归母净利润-7120.5万美元,同比去年增长-26.44%
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益-1.85美元,归母净利润-2452.2万美元,同比去年增长26.69%
|
| 2022-04-28 |
股东大会：
将于2022-06-10召开股东大会
会议内容 ▼▲
- 1.To elect three directors, one to be elected as a Class I director for a term expiring on the date of our 2024 Annual Meeting of Stockholders, and two to be elected as Class II directors for a term expiring on the date of our 2025 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2.To approve an amendment to the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan to increase the number of shares authorized thereunder and modify the fungible plan design.
3.To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2022.
4.An advisory vote to approve Named Executive Officer compensation.
5.To consider such other business as may properly come before the 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”).
|
| 2022-03-18 |
详情>>
业绩披露：
2021年年报每股收益-9.79美元,归母净利润-1.04亿美元,同比去年增长-4.38%
|
| 2021-11-12 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-8.17美元,归母净利润-8338.7万美元,同比去年增长-403.97%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors for a term expiring on the date of our 2024 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2021.
3.An advisory vote to approve Named Executive Officer compensation.
4.To consider such other business as may properly come before the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).
|
| 2021-01-04 |
详情>>
拆分方案：
每6.0000合并分成1.0000股
|
| 2020-07-31 |
股东大会：
将于2020-08-28召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 80,000,000 to 370,000,000. We refer to this proposal in the proxy statement as the “Authorized Common Stock Increase Proposal.”
|
| 2020-07-31 |
股东大会：
将于2020-07-31召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 80,000,000 to 370,000,000. We refer to this proposal in the proxy statement as the “Authorized Common Stock Increase Proposal.”
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of our common stock, with such ratio to be determined in the discretion of our Board of Directors and with such action to be effected at such time and date, if at all, as determined by our Board of Directors within one year after the conclusion of the Special Meeting. We refer to this proposal in the proxy statement as the “Reverse Stock Split Proposal.”
3.To approve one or more adjournments of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve either of Proposal One or Two at the time of the Special Meeting or in the absence of a quorum. We refer to this proposal in the proxy statement as the “Adjournment Proposal.”
|
| 2020-04-28 |
股东大会：
将于2020-06-15召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors for a term expiring on the date of our 2023 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2.To approve the Company’s ability to settle conversions of, and make interest payments on, the Company’s 6.00% Convertible Senior Secured Notes due 2024, which were issued in a private exchange that was completed on December 24, 2019, using shares of the Company’s common stock in excess of 19.99% of the number of outstanding shares of common stock, as required in accordance with Nasdaq Listing Rule 5635(d) (the “Nasdaq Listing Rule Proposal”).
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 80,000,000 to 370,000,000 (the “Authorized Common Stock Increase Proposal”)
4.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of our common stock, with such ratio to be determined in the discretion of our Board of Directors and with such action to be effected at such time and date, if at all, as determined by our Board of Directors within one year after the conclusion of the 2020 Annual Meeting (the “Reverse Stock Split Proposal”)
5.To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2020.
6.An advisory vote to approve Named Executive Officer compensation.
7.To approve one or more adjournments of the 2020 Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve one or more of Proposal Nos. 1 through 6 at the time of the 2020 Annual Meeting or in the absence of a quorum (the “Adjournment Proposal”).
8.To consider such other business as may properly come before the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”).
|
| 2019-04-26 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors for a term expiring on the date of our 2022 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2.To approve the Acorda Therapeutics, Inc. 2019 Employee Stock Purchase Plan.
3.To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2019.
4.An advisory vote to approve Named Executive Officer compensation.
5.To consider such other business as may properly come before the 2019 Annual Meeting of Stockholders (the “2019 Annual Meeting”).
|
| 2018-04-27 |
股东大会：
将于2018-06-27召开股东大会
会议内容 ▼▲
- (1)To elect three Class I directors for a term expiring on the date of our 2021 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
(2)To approve an amendment to the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan to increase the number of shares authorized thereunder.
(3)To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2018.
(4)An advisory vote to approve Named Executive Officer compensation.
(5)To consider such other business as may properly come before the 2018 Annual Meeting of Stockholders (the “2018 Annual Meeting”).
|
| 2017-04-21 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- (1)To elect three Class III directors for a term expiring on the date of our 2020 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
(2)To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2017.
(3)An advisory vote to approve Named Executive Officer compensation.
(4)An advisory vote on the frequency of executive compensation advisory votes.
(5)To consider such other business as may properly come before the 2017 Annual Meeting of Stockholders (the “2017 Annual Meeting”).
|
| 2016-04-29 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- (1)To elect three Class II directors for a term expiring on the date of our 2019 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
(2)To approve an amendment to the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan to increase the number of shares authorized thereunder.
(3)To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2016.
(4)An advisory vote to approve Named Executive Officer compensation.
(5)To consider such other business as may properly come before the 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”).
|
| 2015-04-30 |
股东大会：
将于2015-06-09召开股东大会
会议内容 ▼▲
- 1. To elect two Class I directors for a term expiring on the date of our 2018 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2. To approve the Acorda Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan.
3. To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2015.
4. An advisory vote to approve Named Executive Officer compensation.
5. To consider such other business as may properly come before the 2015 Annual Meeting of Stockholders (the “2015 Annual Meeting”).
|
| 2014-04-25 |
股东大会：
将于2014-06-05召开股东大会
会议内容 ▼▲
- 1. To elect three Class III directors for a term expiring on the date of our 2017 Annual Meeting of Stockholders, or at such time as their successors have been duly elected and qualified.
2. To ratify the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2014.
3. An advisory vote to approve Named Executive Officer compensation.
4. To consider such other business as may properly come before the 2014 Annual Meeting of Stockholders (the “2014 Annual Meeting”).
|